Azro DT 100 mg Tablet 3s

Uses of Azro DT 100 mg Tablet 3s

Azithromycin is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, and sexually transmitted diseases.

Side Effects of Azro DT 100 mg Tablet 3s

GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels. Potentially Fatal: Angioedema and cholestatic jaundice.

Drug Interactions

Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity. Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.

Contraindications

Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.

Mechanism of Action

Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step. Absorption: Rapidly absorbed from the GI tract. Reduced by food (capsule formulation). Absolute bioavailability: Approx 34-52%. Time to peak plasma concentration: Oral tab: 2-3 hr; IV: 1-2 hr. Distribution: Extensive into the tissues (higher than those in blood), WBC (high concentrations), CSF (small amounts). Volume of distribution: 31-33 L/kg. Plasma protein binding (concentration dependent): 7-51% (oral and IV). Metabolism: Hepatic metabolism via demethylation. Excretion: Via bile (as unchanged drug and inactive metabolites); urine (approx 6% of oral dose). Terminal elimination half-life: About 68 hr.

Special Precautions

May increase the risk of torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.